|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
GB8909916D0
(en)
|
1989-04-29 |
1989-06-14 |
Delta Biotechnology Ltd |
Polypeptides
|
|
MX9205293A
(es)
|
1991-09-20 |
1993-05-01 |
Syntex Sinergen Neuroscience J |
Factores neurotrofico derivado del glial
|
|
US20040175795A1
(en)
|
1991-09-20 |
2004-09-09 |
Amgen Inc. |
Glial derived neurotrophic factor
|
|
US5733875A
(en)
|
1994-11-15 |
1998-03-31 |
Amgen Inc. |
Methods of using GDNF as a neuroprotective agent
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
WO1996033731A1
(en)
|
1995-04-26 |
1996-10-31 |
Regeneron Pharmaceuticals, Inc. |
Methods of using neurotrophic factors to enhance neuronal grafts
|
|
US5731284A
(en)
|
1995-09-28 |
1998-03-24 |
Amgen Inc. |
Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
|
|
US6184200B1
(en)
|
1995-09-28 |
2001-02-06 |
Amgen Inc. |
Truncated glial cell line-derived neurotrophic factor
|
|
AU1121997A
(en)
|
1995-11-29 |
1997-06-19 |
Amgen, Inc. |
Method for treating sensory neuropathy using glial cell line-derived neurotrophic factor (gdnf) protein product
|
|
US5641749A
(en)
|
1995-11-29 |
1997-06-24 |
Amgen Inc. |
Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
|
|
US5641750A
(en)
|
1995-11-29 |
1997-06-24 |
Amgen Inc. |
Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
|
|
US5837681A
(en)
|
1996-02-23 |
1998-11-17 |
Amgen Inc. |
Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product
|
|
US5929041A
(en)
|
1996-02-23 |
1999-07-27 |
Amgen Inc. |
Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
|
|
US5741778A
(en)
|
1996-03-19 |
1998-04-21 |
Amgen Inc. |
Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
|
|
US7138251B1
(en)
|
1996-04-22 |
2006-11-21 |
Amgen Inc. |
Polynucleotides encoding a neurotrophic factor receptor
|
|
US6455277B1
(en)
|
1996-04-22 |
2002-09-24 |
Amgen Inc. |
Polynucleotides encoding human glial cell line-derived neurotrophic factor receptor polypeptides
|
|
WO1998054213A2
(en)
|
1997-05-30 |
1998-12-03 |
Amgen Inc. |
Neurotrophic factor receptors
|
|
EP1137774A2
(en)
|
1998-12-09 |
2001-10-04 |
Amgen Inc. |
Grnf4, a gdnf-related neurotrophic factor
|
|
WO2001045746A2
(en)
|
1999-12-24 |
2001-06-28 |
Genentech, Inc. |
Methods and compositions for prolonging elimination half-times of bioactive compounds
|
|
AU2003256613A1
(en)
|
2002-07-19 |
2004-02-09 |
Amgen Inc. |
Protein conjugates with a water-soluble biocompatible, biogradable polymer
|
|
CA2513213C
(en)
*
|
2003-01-22 |
2013-07-30 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
US8946151B2
(en)
|
2003-02-24 |
2015-02-03 |
Northern Bristol N.H.S. Trust Frenchay Hospital |
Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
|
|
KR20120133403A
(ko)
*
|
2004-06-01 |
2012-12-10 |
도만티스 리미티드 |
증강된 혈청 반감기를 가지는 이특이성 융합 항체
|
|
US20060074225A1
(en)
|
2004-09-14 |
2006-04-06 |
Xencor, Inc. |
Monomeric immunoglobulin Fc domains
|
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
|
WO2008022349A2
(en)
*
|
2006-08-18 |
2008-02-21 |
Armagen Technologies, Inc. |
Agents for blood-brain barrier delivery
|
|
EP3176264B1
(en)
*
|
2007-05-30 |
2018-09-26 |
Postech Academy-Industry- Foundation |
Immunoglobulin fusion proteins
|
|
US20110045007A1
(en)
*
|
2007-05-31 |
2011-02-24 |
Genmab A/S |
Fusion or linked proteins with extended half life
|
|
WO2009070597A2
(en)
*
|
2007-11-26 |
2009-06-04 |
Armagen Technologies, Inc. |
Fusion proteins for delivery of gdnf to the cns
|
|
CA2764777A1
(en)
|
2009-06-11 |
2010-12-16 |
Angiochem Inc. |
Fusion proteins for delivery of gdnf and bdnf to the central nervous system
|
|
EP2504360B1
(en)
|
2009-11-23 |
2018-08-15 |
Amgen Inc. |
Monomeric antibody fc
|
|
ES2608835T3
(es)
|
2011-04-13 |
2017-04-17 |
Bristol-Myers Squibb Company |
Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones
|
|
EP3068891A1
(en)
*
|
2013-11-13 |
2016-09-21 |
Aequus Biopharma Inc. |
Engineered glycoproteins and uses thereof
|
|
WO2015143199A1
(en)
*
|
2014-03-20 |
2015-09-24 |
Bristol-Myers Squibb Company |
Serum albumin-binding fibronectin type iii domains
|
|
AU2017357931B2
(en)
|
2016-11-10 |
2024-12-05 |
Keros Therapeutics, Inc. |
GDNF fusion polypeptides and methods of use thereof
|